

## ANSWERING REVIEWERS

Reviewer's code: O5469244

## SPECIFIC COMMENTS TO AUTHORS

Recent studies have found that circRNA_0001658 features prominently in the progression of tumors through being a biomarker for the diagnosis and prognosis. Such as, circ_0001658 is highly expressed in osteosarcoma, and overexpression of this circRNA promotes the proliferation and metastasis. How circ_0001658 interferes with the progression of $C R C$ are not clear. miR-590-5p is lowly expressed in colorectal cancer tissues and cells, and is related to adverse clinical and pathological indicators in patients; miR-590-5p overexpression inhibits the growth and migration of colorectal cancer cells. This study designed to analysis the Hsa_circ_0001658 accelerates the progression of colorectal cancer through miR-590-5p/METTL3 regulatory axis. The study is well designed, methods are clearly described. The authors found that the circ_0001658 could specifically bind to miR-590-5p and negatively modulate its expressions; METTL3 was a target of $m i R-590-5 p$ and can be positively modulated by circ_0001658. Overall, this study is very interesting, and the

7041 Koll Center Parkway,
Suite 160 , Pleasanton, CA 94566, USA

Telephone:
results are well discussed. Minor comments: 1. The aim of the study should be described in detail in the abstract. 2. Some minor language polishing should be revised. 3. The quality of the figures should be improved. 4. References should be edited and updated. 5. The limit of the study should be discussed.

Response: Thank you for your comments.
The language has been improved, and the references have been updated.
The limitation of the present study has been discussed.
Additionally, we also provided the figures with higher quality to you.
Reviewer's code: O5483283

## SPECIFIC COMMENTS TO AUTHORS

This is an interesting study of miR-590-5p/METTL3 regulatory axis and colorectal cancer. The study was performed well, and the results are attractive. The manuscript should be edited before the final acceptance.

Response: Thank you for your positive comments.

